{"id":"letermovir-for-secondary-prophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Elevated creatinine"}]},"_chembl":{"chemblId":"CHEMBL1241951","moleculeType":"Small molecule","molecularWeight":"572.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Letermovir is a non-nucleoside inhibitor that targets the CMV terminase enzyme, which is essential for packaging newly synthesized viral DNA into virions. By blocking this step, the drug prevents the formation of infectious CMV particles without requiring viral DNA polymerase inhibition, offering a distinct mechanism from traditional antivirals. This makes it particularly useful for prophylaxis in immunocompromised patients at high risk of CMV disease.","oneSentence":"Letermovir inhibits the cytomegalovirus (CMV) terminase complex, preventing viral DNA packaging and replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:46.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary prophylaxis of cytomegalovirus (CMV) infection in CMV-seropositive recipients of hematopoietic stem cell or solid organ transplant"}]},"trialDetails":[{"nctId":"NCT06407232","phase":"PHASE3","title":"Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-08-08","conditions":"Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant","enrollment":90},{"nctId":"NCT05626530","phase":"PHASE4","title":"Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients","status":"RECRUITING","sponsor":"Tufts Medical Center","startDate":"2023-02-02","conditions":"Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia","enrollment":25},{"nctId":"NCT05914701","phase":"PHASE4","title":"Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-07-01","conditions":"To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation","enrollment":31},{"nctId":"NCT03728426","phase":"PHASE2","title":"Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection","status":"COMPLETED","sponsor":"Amy C. Sherman, MD","startDate":"2019-01-11","conditions":"Cytomegalovirus Infections","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["secondary prophylaxis of CMV reactivation"],"phase":"marketed","status":"active","brandName":"Letermovir for secondary prophylaxis","genericName":"Letermovir for secondary prophylaxis","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Letermovir inhibits the cytomegalovirus (CMV) terminase complex, preventing viral DNA packaging and replication. Used for Secondary prophylaxis of cytomegalovirus (CMV) infection in CMV-seropositive recipients of hematopoietic stem cell or solid organ transplant.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}